Accropeutics

About Accropeutics

Accropeutics, a part of Accro Bioscience (Suzhou) Limited, is a clinical-stage biotech company dedicated to the discovery and development of innovative drugs for inflammation, autoimmune diseases, fibrosis, and cancer. The company focuses on the 'Cell Death - Inflammation' loop and has established a unique 'Regulated Cell Death' drug discovery platform.

Products & Services

AC-201:An oral, selective TYK2/JAK1 inhibitor being developed for moderate-to-severe plaque psoriasis and non-infectious uveitis.

AC-101:A novel RIPK2 inhibitor in development for the treatment of moderate-to-severe Ulcerative Colitis (UC).

Specialties

Regulated Cell Death Drug Discovery and Development Inflammation Autoimmune Diseases Fibrosis Cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B Plus T: - FT: Series B Plus	A: 12000000 MR: - FA: $12 million FAN: 12000000	D: 2025-03-14 FD: 2025-03-14	4 investors

Series B Plus Latest

2025-03-14

$12.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

X

Xiaohu (Jason) Zhang Ph.D.

Co-founder & CEO

S

Sudan He Ph.D.

Co-founder & Chief Scientific Advisor

K

Kenneth Gao

SVP, Corporate Development & Strategy

M

Ms. Cindy Li

Head of Clinical Development

S

Sanmao Kang Ph.D.

Vice President of Preclinical

H

Haikuo Ma Ph.D.

VP of Medicinal Chemistry and CMC

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Accropeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised